The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second ...
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Soliqua 100/33 (insulin glargine/lixisenatide ... Keep reading to learn more about Soliqua 100/33’s dosage, side effects, uses, and more. Soliqua 100/33 comes as a liquid solution inside ...
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback